Severe acute respiratory syndrome coronavirus 2 Spike protein and conserved T cell epitopes (SARS-CoV-2 S protein and T-cell epitopes)

The SARS-CoV-2 Spike protein and conserved T cell epitopes represent a multi-antigen target strategy designed to elicit broad and durable immunity against COVID-19. The Spike protein, particularly its receptor-binding domain (RBD), is the primary mediator of viral entry into host cells by interacting with the ACE2 receptor and is the main target for neutralizing antibodies (Wang et al., 2022, J. Clin. Invest.). By incorporating conserved T cell epitopes from other viral proteins such as the Nucleocapsid (N), Membrane (M), and non-structural proteins (NSPs), this target approach aims to overcome the limitations of Spike-only vaccines, which are susceptible to viral mutations and variant escape (Grifoni et al., 2020, Cell). These conserved regions are less prone to mutation and are recognized by cytotoxic T lymphocytes (CD8+) and helper T cells (CD4+), providing a second line of defense that can clear infected cells and reduce disease severity (Sette & Crotty, 2021, Cell). This combined target is utilized in next-generation vaccine candidates, such as UB-612, to provide pan-variant protection by priming the immune system to recognize both the surface proteins and internal viral machinery (Kuo et al., 2022, medRxiv/Lancet). Therapeutic interventions targeting these components work by ensuring a robust, multi-layered immune response that remains effective even as the virus evolves.

Other names

SARS-CoV-2 multi-antigen targetSpike and non-spike T-cell epitopesSARS-CoV-2 pan-variant vaccine targetMultitope SARS-CoV-2 antigenSARS-CoV-2 S, N, M, and NSP epitopes

Induction of neutralizing antibodies via the Spike protein and activation of broad, cross-reactive CD4+ and CD8+ T-cell responses via conserved epitopes to prevent viral entry and clear infected cells.